X4 Pharmaceuticals shares rise 10.11% intraday after Guggenheim initiates Buy rating with $12 target.

X4 Pharmaceuticals surged 10.11% intraday following Guggenheim’s initiation of coverage with a Buy rating and $12 price target, more than triple its current trading price of $3.97. The analyst cited mavorixafor’s potential as a first-in-class oral CXCR4 antagonist in Phase 3 trials for chronic neutropenia, alongside a strengthened balance sheet from $240.3M in recent financing that extends cash runway to 2028. The report emphasized the drug’s differentiated hematology profile and a 2026 clinical catalyst timeline, positioning the stock for substantial upside. While broader biotech sentiment and institutional validation for peers like Tango Therapeutics and Immuneering were noted, Guggenheim’s high-conviction entry was the direct catalyst for X4’s sharp intraday rally.